ENPICOM introduces an end-to-end solution for fast and efficient antibody discovery Kumar Jeetendra | January 29, 2021 ‘s-Hertogenbosch (The Netherlands) –ENPICOM BV, an innovative bioinformatics software engineering company, announces a major release of its ImmunoGenomiX (IGX) Platform featuring the new Antibody Discovery Module (ADM). This solution will allow scientists in biopharmaceutical companies and academia, as well as service providers working in the antibody discovery field, to make the most of their Sanger …
New gene based vaccine procedure gets award from the Bill and Melinda Gates Foundation Kumar Jeetendra | January 29, 2021 The AAVCOVID vaccine application, a novel gene-based vaccine plan that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. The grant will assist the effort to bring further preclinical validation into the AAV vaccine platform. An AAVCOVID vaccine candidate is set to …
Novel hydrogel gradually delivers RNA nanovaccines to shrivel tumors Kumar Jeetendra | February 18, 2021 Messenger RNA (mRNA) vaccines to stop COVID-19 have made headlines around the world recently, but scientists also have been working on mRNA vaccines to treat or prevent other diseases, including some forms of cancer. Cancer immunotherapy vaccines operate similarly to mRNA vaccines for COVID-19, except they trigger the immune system to attack tumors rather than …
Killing antibodies actuated by COVID-19 vaccines less successful against new variants Kumar Jeetendra | March 15, 2021 SARS-CoV-2, the virus that causes COVID-19, has mutated through the pandemic. New variants of this virus have arisen around the world, including variants that might possess increased capacity to spread or evade the immune system. Such variations have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Recognizing how well the COVID-19 vaccines …
Small SARS-CoV-2 protein may have huge ramifications for future COVID-19 medicines Kumar Jeetendra | April 12, 2021 A very small protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future therapies, according to a team of Penn State researchers. Using a novel toolkit of approaches, the scientists uncovered the first full structure of the Nucleocapsid (N) protein and discovered how antibodies from COVID-19 patients interact with …
Researchers enlighten how a few antibodies can viably disable ebolaviruses Kumar Jeetendra | April 18, 2021 Some survivors of ebolavirus outbreaks create antibodies that may broadly neutralize those viruses–and today , scientists at Scripps Research have illuminated how these antibodies can disable the viruses so efficiently. The insights might be helpful for developing effective treatments. Ebolavirus is a family of often-deadly viruses that includes Ebola virus and lots of lesser-known viruses …
FDA denies EUA for monoclonal antibody treatment bamlanivimab to treat patients with COVID Kumar Jeetendra | April 18, 2021 Now, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody treatment bamlanivimab, when administered alone, to be utilized for treating mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants …
New expected objective for treating metastasized oral malignant melanoma in dogs Kumar Jeetendra | April 23, 2021 Scientists have shown that the biological molecule PD-L1 is a possible target for the treatment of metastasized oral malignant melanoma in dogs. There are a number of cancers that affect dogs, but there are far fewer diagnosis and treatment options for these canine cancers. However, because dogs and humans are both mammals, it is very …
Biotinylated Heparan Sulfate Antibodies Kumar Jeetendra | April 29, 2021 AMSBIO has launched two new biotinylated formats of the 10E4 Heparan Sulfate antibody (high and low biotin) along with a starter pack to allow scientists to test both formats at a reduced cost. Heparan Sulfate (HS) is a highly sulfated linear polysaccharide that is attached to a core protein to form HS Proteoglycans on the …
Too soon to say second wave has topped; immunization accessibility national bottleneck: CRISIL Kumar Jeetendra | May 17, 2021 Even as new COVID-19 infections have shown a declining trend, credit rating agency Crisil on Monday said it is “too early” to say that the second wave of the pandemic has peaked and flagged concerns over the vaccination drive. After opening up the vaccination for all adults, the drive has suffered because availability of vaccines …
Mild cases of COVID-19 give enduring antibody, shows study Kumar Jeetendra | May 24, 2021 Months after recovering from mild cases of COVID-19, people still possess immune cells in their body pumping out antibodies against the virus that causes COVID-19, according to a study from researchers at Washington University School of Medicine in St. Louis. Such cells could persist for a lifetime, churning out antibodies all of the while. The …
We didn’t back multiplying of vaccine dosing gap: Indian researchers Kumar Jeetendra | June 16, 2021 The Indian government doubled the gap between the two doses of the AstraZeneca COVID-19 vaccine without the agreement of the scientific group that it said recommended the increase, three members of the advisory body told Reuters. The ministry of health announced the decision to change the gap from 6-8 weeks to 12-16 weeks on May …
